Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. - Wikidata - awgldk - TriplyDB

Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.

Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.

http://www.wikidata.org/entity/Q33157356

about

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association Calsequestrin 2 and arrhythmias Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human Drug therapy in cardiac arrest: a review of the literature Next-Generation Sequencing in Post-mortem Genetic Testing of Young Sudden Cardiac Death Cases Catecholaminergic polymorphic ventricular tachycardia: An exciting new era Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death.Molecular autopsy in victims of inherited arrhythmias Inherited ion channel diseases: a brief review Recent advances in genetic testing and counseling for inherited arrhythmias Current topics in catecholaminergic polymorphic ventricular tachycardia 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis Exome Analyses of Long QT Syndrome Reveal Candidate Pathogenic Mutations in Calmodulin-Interacting Genes Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models Heart disease and stroke statistics--2014 update: a report from the American Heart Association Heart disease and stroke statistics--2012 update: a report from the American Heart Association Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.Risk stratification in electrical cardiomyopathies.Risk stratification in young patients with channelopathies.Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations.The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.Catecholaminergic polymorphic ventricular tachycardia in a patient with recurrent exertional syncope Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.[Ion channel diseases in children].Sudden cardiac arrest during sex in patients with either catecholaminergic polymorphic ventricular tachycardia or long-QT syndrome: a rare but shocking experience.Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].Catecholaminergic Polymorphic Ventricular Tachycardia with QT Prolongation.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome.Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.Impact of genetics on the clinical management of channelopathies.Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.

P2860

Q22306356-3C24E8C4-118E-48F1-81BB-EF1CB6E9CA32 Q24300626-FE6D35AF-4A9B-4C57-BE0A-7D97F9B60ECB Q24307681-61DAE3DF-C1CD-46EF-9F50-3D1A404466C1 Q26741074-9A6CE842-5C89-4BFE-A25B-6092ABAC068D Q26745883-900FEC75-ED2F-46D6-808D-830E356C1C7D Q26747056-2580321A-9E8C-4F63-92A4-9ADE1CE5800D Q27339434-E8F561B8-75D7-4B2F-A641-7CE5BC6B86B0 Q28069286-4EF4636A-778F-4DB6-9C3A-96A17AAFDCF7 Q28071914-7C70EF0C-2F0F-4EAB-AD86-5E86056997CD Q28074154-89B5B96D-ED82-47B4-9ABC-4E95339D90CC Q28076784-657814CD-B3F6-4114-A3A4-87B02830972B Q28087002-B0881605-D194-45A6-BEE5-154C6D7FA8BD Q28262015-7CD5B320-82D1-4B05-BF7C-57A5C6025219 Q28308142-A8183AFF-6ABD-470E-9A11-63339274F148 Q28546038-69D5EB1E-AC53-4827-A94F-7405B4AA23B9 Q28547114-C45AED69-7E76-4D97-9D73-E0DC73E5111A Q29547691-9BC1FB51-7071-4A84-B9B1-C74A3D076F58 Q29547909-309A60EF-5A82-4A15-9D5F-6BC674C1A124 Q30238784-0DC39E2B-ED2E-44C9-8D9A-DA75D160CF0B Q30498471-999A6E50-F17F-4697-8D15-FF95F4647101 Q33158278-69749E96-84D9-494A-87B8-A0E5F6426EC8 Q33158864-FF9086CB-8CC7-4715-9C9A-C106C75B2C59 Q33160416-F850F33E-007F-4920-B5CA-F964C8A3C2BD Q33160839-6C6E9233-B370-49E0-AE18-74D59EFAB558 Q33161041-49151F75-B118-4A9B-B33E-12F75825A481 Q33161060-2F6518C6-CCEE-4FD5-9A10-8EDC1E6D320D Q33162208-FA78ACA8-F948-4919-BCCF-82C59E7495A5 Q33164649-16160AB8-E882-4DA1-9D53-825281C78664 Q33165068-3AC8AC67-42CB-4B06-9FE0-14F0C3F2AA42 Q33165339-075B6D99-E472-441C-B2EF-63EAAF7B3F61 Q33165762-F4269BA8-8AC4-4F9A-A6A5-412F8C004C16 Q33166105-5B015AB7-D528-4EEC-BEC6-13F3B3DC831C Q33167418-BA20171A-8E90-4379-8482-C55B5FD2703D Q33603766-ED23E417-4BA1-412B-9CE3-FBA65CA98C5B Q33919047-B1FCF491-83B1-4812-87B4-4A176A74773F Q33940815-553EA762-0BEA-4EC6-B1A1-B436F1F55CD9 Q34036797-93E0DEE9-50AA-45B3-AD10-BFD3B62A941C Q34160930-D03B4F04-E006-41E7-B137-C7C48B9526DE Q34629553-37B26BF3-23D0-4BDE-9C4C-E023878B1568 Q35242390-8C48F5C3-0EB4-42C9-8F95-747B25AC2046

P2860

Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.

http://www.wikidata.org/entity/Q33157356

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Incidence and risk factors of ...... rphic ventricular tachycardia.

@ast

Incidence and risk factors of ...... rphic ventricular tachycardia.

@en

type

label

Incidence and risk factors of ...... rphic ventricular tachycardia.

@ast

Incidence and risk factors of ...... rphic ventricular tachycardia.

@en

prefLabel

Incidence and risk factors of ...... rphic ventricular tachycardia.

@ast

Incidence and risk factors of ...... rphic ventricular tachycardia.

@en

P1433

Q33157356-B5FE835C-42A6-4FDC-922A-A4064CEA9919

P1476

Q33157356-2C5EE3F6-CE31-4A71-934C-378C8A183ACA

P2093

Q33157356-0DB768B3-D927-488F-B8E3-C8A17331A324

Q33157356-22D7D770-5A8A-494C-AD51-B7B8725990A7

Q33157356-2AA08888-A585-48C8-B5AC-30A4F1E6D20C

Q33157356-3CDFD002-4374-46FF-A554-6EA1EC782366

Q33157356-5A3E944C-5BDA-41ED-BAB3-381478AE4A93

Q33157356-5ABB0527-7ABE-4A0E-BC91-D01BE91B77F2

Q33157356-5B04FE57-B603-4F01-A95D-33E3FF5749AB

Q33157356-A507735D-796E-4F80-B1B2-51151AFD0EC0

Q33157356-A8364293-99B1-4442-B8DC-3550D201D93C

Q33157356-AC9CA9B8-2040-4190-8E64-219197CF8AE8

P304

Q33157356-8AC4D0D3-0AB8-43A7-8BCA-BA4A8B664DB2

P31

Q33157356-312648F2-6279-41BE-A5A8-DED003743E1E

P356

Q33157356-A22323A8-5F74-4FDD-AFD9-E313EACDB656

P407

Q33157356-4A603B12-2248-427C-8EA6-3732BEC9208A

P433

Q33157356-25CF5ACF-7721-43DD-8A25-FDC517E9FB97

P478

Q33157356-8BD31495-D7DD-4192-981B-EB3FC0453A1F

P50

Q33157356-28D6EEF0-D060-4252-BA70-1EBD14DBF4BD

Q33157356-9B0E2128-261D-41AF-B86F-079F4E0FDCB5

P577

Q33157356-63B17102-DE44-4FCF-8FEA-DC79C118396A

P698

Q33157356-409CF116-2AED-4883-BD14-E1D698022268

P921

Q33157356-C7E90F0A-7B56-40B7-9692-C7F09056A18E

Q33157356-F9533052-CB46-4CD9-BB23-0278DF7BE2F9

P356

CIRCULATIONAHA.108.829267

P1433

P1476

Incidence and risk factors of ...... rphic ventricular tachycardia.

@en

P2093

Alice Maltret

http://www.w3.org/2001/XMLSchema#string

Anne Messali

http://www.w3.org/2001/XMLSchema#string

Antoine Leenhardt

http://www.w3.org/2001/XMLSchema#string

Didier Klug

http://www.w3.org/2001/XMLSchema#string

Elisabeth Villain

http://www.w3.org/2001/XMLSchema#string

Isabelle Denjoy

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Lupoglazoff

http://www.w3.org/2001/XMLSchema#string

Joël Kamblock

http://www.w3.org/2001/XMLSchema#string

Joël Lunardi

http://www.w3.org/2001/XMLSchema#string

Meiso Hayashi

http://www.w3.org/2001/XMLSchema#string

P304

2426-2434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.829267

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Pascale Guicheney

Fabrice Extramiana

P577

2009-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19398665

http://www.w3.org/2001/XMLSchema#string

P921

catecholaminergic polymorphic ventricular tachycardia